Search

Your search keyword '"Matt, Coffey"' showing total 46 results

Search Constraints

Start Over You searched for: Author "Matt, Coffey" Remove constraint Author: "Matt, Coffey"
46 results on '"Matt, Coffey"'

Search Results

1. Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects

2. 582 Analysis of the HR+/HER2- breast cancer tumor microenvironment following immune priming with pelareorep and atezolizumab using imaging mass cytometry – Results from the AWARE-1 trial

Catalog

Books, media, physical & digital resources

3. Oncolytic Reovirus-Mediated Recruitment of Early Innate Immune Responses Reverses Immunotherapy Resistance in Prostate Tumors

4. Oncolytic virus-derived type I interferon restricts CAR T cell therapy

5. Immune characterization of metastatic colorectal cancer patients post reovirus administration

6. Combination Therapy with Reovirus and ATM Inhibitor Enhances Cell Death and Virus Replication in Canine Melanoma

7. Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche

8. 806 Changes in T cell clonality in AWARE-1 study, a window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer

10. Supplementary Figure 3 from Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment

11. Supplementary Table 1 from Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment

12. Supplementary Figure 6 from Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment

13. Supplementary Figure legends from Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment

14. Supplementary Figure 2 from Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment

15. Supplementary Figure 5 from Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment

16. Supplementary Figure 4 from Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment

17. Supplementary Figure 1 from Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment

18. Data from Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment

19. Supplementary Figures S1-S4 from Enhanced In vitro and In vivo Cytotoxicity of Combined Reovirus and Radiotherapy

20. Data from Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study

21. Data from Phase I Trial of Cyclophosphamide as an Immune Modulator for Optimizing Oncolytic Reovirus Delivery to Solid Tumors

22. Supplementary Data from Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study

23. Supplementary Figure 1 from Phase I Trial of Cyclophosphamide as an Immune Modulator for Optimizing Oncolytic Reovirus Delivery to Solid Tumors

24. Supplementary Figure Legends 1-3 from Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies

25. Supplementary Figure 1 from Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies

26. Supplementary Figure 2 from Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies

27. Data from Two-Stage Phase I Dose-Escalation Study of Intratumoral Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers

28. Supplementary Data from Two-Stage Phase I Dose-Escalation Study of Intratumoral Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers

29. Supplementary Figure 3 from Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies

30. Data from Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies

31. Data from Enhanced In vitro and In vivo Cytotoxicity of Combined Reovirus and Radiotherapy

34. Oncolytic virus–mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice

35. Proteasome inhibition enhances myeloma oncolytic reovirus therapy by suppressing monocytic anti-viral immune responses

36. Abstract PD4-03: PD4-03 Pelareorep primes the tumor for checkpoint inhibition therapy by activating the interferon-gamma signaling pathway and tumor inflammation signature in early breast cancer patients - results of the AWARE-1 trial

37. Phase I trial of sargramostim/pelareorep therapy in pediatric patients with recurrent or refractory high-grade brain tumors

38. Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses

39. Oncolytic virus treatment differentially affects the CD56

40. Abstract 6354: Using imaging mass cytometry to visualize the multiple myeloma tumor microenvironment post immune priming

41. Oncolytic reovirus in canine mast cell tumor.

42. Abstract 2272: Exploratory analysis of T cell repertoire dynamics upon systemic treatment with the oncolytic virus pelareorep in combination with pembrolizumab and chemotherapy in patients with advanced pancreatic adenocarcinoma

43. EMS pilots: Selecting the very best

44. Efficacy and safety evaluation of human reovirus type 3 in immunocompetent animals: racine and nonhuman primates

45. The oncolytic effects of reovirus in canine solid tumor cell lines.

46. 174. Process Development of a Scaleable Purification Protocol for the Production of Reolysin, an Oncolytic, Reovirus-Based Therapeutic